| Jason Chen, DO, MS | |
|
5420 West Loop S Ste 1100, Bellaire, TX 77401-2115 | |
| (713) 486-5590 | |
| (713) 486-0879 |
| Full Name | Jason Chen |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 13 Years |
| Location | 5420 West Loop S Ste 1100, Bellaire, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407148604 | NPI | - | NPPES |
| 366830301 | Medicaid | TX | |
| 8GB063 | Other | TX | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081P2900X | Physical Medicine & Rehabilitation - Pain Medicine | Q8855 (Texas) | Primary |
| 208100000X | Physical Medicine & Rehabilitation | Q8855 (Texas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sugar Land Surgical Hospital Llp | Sugar land, TX | Hospital |
| Memorial Hermann - Texas Medical Center | Houston, TX | Hospital |
| Memorial Hermann Sugar Land Hospital | Sugar land, TX | Hospital |
| Memorial Hermann Hospital System | Houston, TX | Hospital |
| Memorial Hermann Memorial City Hospital | Houston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Select Physical Therapy Texas Limited Partnership | 6608868070 | 529 |
| Ut Physicians | 8426960360 | 1400 |
News Archive
A glucosamine-like dietary supplement suppresses the damaging autoimmune response seen in multiple sclerosis, according to a UC Irvine study.
An article in Journal of Applied Microbiology investigates how bacteria respond when they are subjected to environmental alterations, such as those of space stations, which feature lowered effects of gravity.
Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.
The National Institutes of Health, an agency of the U.S. Department of Health and Human Services, and the Wellcome Trust, a global charity based in London, today announced a partnership to support population-based genetic studies in Africa of common, non-communicable disorders such as heart disease and cancer, as well as communicable diseases such as malaria.
› Verified 4 days ago
| Entity Name | Ut Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033157821 PECOS PAC ID: 8426960360 Enrollment ID: O20031107000268 |
News Archive
A glucosamine-like dietary supplement suppresses the damaging autoimmune response seen in multiple sclerosis, according to a UC Irvine study.
An article in Journal of Applied Microbiology investigates how bacteria respond when they are subjected to environmental alterations, such as those of space stations, which feature lowered effects of gravity.
Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.
The National Institutes of Health, an agency of the U.S. Department of Health and Human Services, and the Wellcome Trust, a global charity based in London, today announced a partnership to support population-based genetic studies in Africa of common, non-communicable disorders such as heart disease and cancer, as well as communicable diseases such as malaria.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason Chen, DO, MS 5420 West Loop S Ste 1100, Bellaire, TX 77401-2115 Ph: (713) 486-5590 | Jason Chen, DO, MS 5420 West Loop S Ste 1100, Bellaire, TX 77401-2115 Ph: (713) 486-5590 |
News Archive
A glucosamine-like dietary supplement suppresses the damaging autoimmune response seen in multiple sclerosis, according to a UC Irvine study.
An article in Journal of Applied Microbiology investigates how bacteria respond when they are subjected to environmental alterations, such as those of space stations, which feature lowered effects of gravity.
Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.
The National Institutes of Health, an agency of the U.S. Department of Health and Human Services, and the Wellcome Trust, a global charity based in London, today announced a partnership to support population-based genetic studies in Africa of common, non-communicable disorders such as heart disease and cancer, as well as communicable diseases such as malaria.
› Verified 4 days ago
Kemly Philip, MD PHD MBE Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 5420 West Loop S Ste 1100, Bellaire, TX 77401 Phone: 713-486-5590 Fax: 713-486-0879 | |
Dr. John Christopher Cianca, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 5959 West Loop S, Suite 260, Bellaire, TX 77401 Phone: 713-627-3156 Fax: 713-627-0393 |